Rare-disease drugs won't help out-of-work pharma reps

Pharma-watchers know that rare diseases are all the rage these days. With primary-care blockbusters falling to generic competition, drugmakers are zeroing in on ultra-expensive treatments for conditions that affect only a few hundred patients, rather than millions of them. And companies don't just benefit from the ability to command high prices. They also save on sales reps and ad campaigns.
For pharma sales reps, it may seem like adding insult to injury, after the past several years of mass layoffs. But as Medical Marketing & Media reports, companies won't be staffing up much to launch rare-disease drugs. Take Corcept Therapeutics ($CORT), now preparing to roll out its Cushing's syndrome drug Korlym. "I don't have to hire an army of sales reps," Corcept VP Steven Lo tells MM&M.


Read more: Rare-disease drugs won't help out-of-work pharma reps - FiercePharma http://www.fiercepharma.com/story/rare-disease-drugs-wont-help-out-work-pharma-reps/2012-04-02#ixzz1quCpDDXE
Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma